AlphAIalphai — Financial news for AI agents
MarketBeatMAY 13 min read$NSP

JPMorgan Chase & Co. Lowers Insperity (NYSE:NSP) Price Target to $33.00

JPMorgan Chase & Co. has lowered its price target for Insperity (NYSE:NSP) from $35.00 to $33.00, maintaining an "underweight" rating, which still implies a 13.75% potential upside. This adjustment comes after Insperity's stock plunged 18.4% to $29.01 due to weakened worksite employee volume and negative profitability metrics, despite insider buying from CEO Paul J. Sarvadi. The company also announced lowered guidance for Q2 and the full fiscal year 2026.

Original reporting
MarketBeat · MarketBeat
Published May 1, 2026, 6:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
JPMorgan Chase & Co. Lowers Insperity (NYSE:NSP) Price Target to $33.00 — source image
Source · MarketBeat
Decision brief

The 30-second read

$NSPBearishMed
01

Why it matters

The downgrade signals institutional concern, likely leading to continued short-term pressure, but long-term prospects depend on operational recovery.

02

Market read

The news is highly relevant for traders holding or considering positions in NSP and related HR services stocks, indicating increased volatility and risk.

03

What to watch

Potential macroeconomic tailwinds or sector-specific catalysts not yet reflected in stock price.

Timing: Immediate to short-term (next 1-3 weeks)

Background

JPMorgan's downgrade and price target reduction follow Insperity's recent earnings report showing weakened profitability and lower guidance, compounded by an 18.4% stock plunge.

Company-level read

Ticker impact

$NSPBearishMedium confidence
Context

Primary focus due to recent price target change and stock plunge.

Expected impact

Moderate short-term decline expected, potential stabilization or slight rebound if fundamentals improve.

Evidence & confidence

The significant stock decline and lowered target reflect negative sentiment, but insider buying and potential support levels could mitigate further downside.

Market effects

Sector

Negative sentiment may pressure the HR and professional services sector.

Regional

Limited regional impact; primarily affects US-based HR service stocks.

Global

Minimal global market impact, specific to sector and region.

Counterpoint

What could challenge this read

Insperity's insider buying and potential for operational improvements could lead to a recovery, making current decline an overreaction.

Key entities

  • Financial Institution
    JPMorgan Chase & Co.

    Major investment bank issuing the downgrade.

  • Company
    Insperity

    Provider of HR and business performance solutions, recently downgraded.

Read at source← All news

Related articles

JUL 31
$NSPMedAI 8/10

Insperity (NSP) Stock Trades Down, Here Is Why

Insperity (NYSE: NSP) shares fell about 7.3% after its Q2 results and full-year guidance. The company reported adjusted EPS above its midpoint, but benefits costs per covered employee rose 5.2% and total gross profit fell 3%. Guidance also pointed to paid worksite employees declining about 1% to 1.6% in 2026.

financialcontent.com5 min
JUL 29
$NSPMed

Insperity (NYSE:NSP) Surprises With Q2 CY2026 Sales

Insperity (NYSE:NSP) reported Q2 CY2026 revenue of $1.69 billion, up 1.7% year over year, beating Wall Street’s revenue estimate by 0.7%. Non-GAAP adjusted EPS was $0.34, up from $0.26, and 6.9% above consensus. The article cites full-year EPS expected to rise from $0.85 to $2.34.

financialcontent.com6 min
JUL 29
$NSPMed

INSPERITY, INC. (NSP): Results of Operations and Financial Condition

INSPERITY, INC. (NSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Insperity Announces Second Quarter Results HOUSTON – July 29, 2026 – Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for America’s best businesses, today reported results for the second quarter ended June 30, 2026

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min